

Eric Tse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6391832/publications.pdf>

Version: 2024-02-01

119
papers

6,539
citations

94269

37
h-index

69108

77
g-index

126
all docs

126
docs citations

126
times ranked

8729
citing authors

#	ARTICLE	IF	CITATIONS
1	Recent Advances in the Diagnosis and Treatment of Natural Killer Cell Malignancies. <i>Cancers</i> , 2022, 14, 597.	1.7	4
2	Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5670.	1.8	1
3	How we treat NK/T-cell lymphomas. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	41
4	Arsenic trioxide targets Hsp60, triggering degradation of p53 and survivin. <i>Chemical Science</i> , 2021, 12, 10893-10900.	3.7	22
5	Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins. <i>Blood Cancer Discovery</i> , 2021, 2, 388-401.	2.6	26
6	Venous thromboembolism in Asia and worldwide: Emerging insights from GARFIELD-VTE. <i>Thrombosis Research</i> , 2021, 201, 63-72.	0.8	14
7	Arsenic trioxide inhibits anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma through targeting ALK-fusion oncoprotein. <i>British Journal of Haematology</i> , 2021, 194, 1085-1090.	1.2	2
8	ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis. <i>Blood</i> , 2021, 138, 2403-2403.	0.6	1
9	Multiplex Single-Cell Analysis of Cancer Cells Enables Unbiased Uncovering Subsets Associated with Cancer Relapse: Heterogeneity of Multidrug Resistance in Precursor B-ALL. <i>ChemMedChem</i> , 2021, , .	1.6	2
10	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	0.6	1
11	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. <i>Leukemia</i> , 2020, 34, 3413-3419.	3.3	42
12	Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long-term results and unique prognostic indicators. <i>Cancer</i> , 2020, 126, 3244-3254.	2.0	17
13	Risk assessment of venous thromboembolism in hematological cancer patients: a review. <i>Expert Review of Hematology</i> , 2020, 13, 471-480.	1.0	4
14	C3 Inhibition with Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Paddock and Palomino Trials. <i>Blood</i> , 2020, 136, 3-4.	0.6	4
15	Low-dose nivolumab induced durable complete response in relapsed primary central nervous system diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 2227-2230.	0.8	8
16	Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas. <i>Expert Review of Hematology</i> , 2019, 12, 927-935.	1.0	21
17	NK/T-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 253-261.	0.7	41
18	Chaperone activation and client binding of a 2-cysteine peroxiredoxin. <i>Nature Communications</i> , 2019, 10, 659.	5.8	32

#	ARTICLE	IF	CITATIONS
19	Targeting PIN1 as a Therapeutic Approach for Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 369.	1.8	14
20	Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomasâ€”Implications for Therapy. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 37-43.	1.2	6
21	Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. <i>Cancer</i> , 2018, 124, 2316-2326.	2.0	43
22	Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. <i>Annals of Oncology</i> , 2018, 29, 256-263.	0.6	61
23	PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing l-asparaginase: efficacy and safety. <i>Annals of Hematology</i> , 2018, 97, 193-196.	0.8	83
24	Positron emission tomography computed tomography features of monomorphic epitheliotropic intestinal T-cell lymphoma. <i>Hematology</i> , 2018, 23, 10-16.	0.7	22
25	PIN1 in Cell Cycle Control and Cancer. <i>Frontiers in Pharmacology</i> , 2018, 9, 1367.	1.6	38
26	Cell Cycle-Dependent Uptake and Cytotoxicity of Arsenic-Based Drugs in Single Leukemia Cells. <i>Analytical Chemistry</i> , 2018, 90, 10465-10471.	3.2	25
27	Polyphosphate Stabilizes Protein Unfolding Intermediates as Soluble Amyloid-like Oligomers. <i>Journal of Molecular Biology</i> , 2018, 430, 4195-4208.	2.0	45
28	Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2018, 132, 2314-2314.	0.6	18
29	PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. <i>Blood</i> , 2017, 129, 2437-2442.	0.6	399
30	The diagnosis and management of NK/T-cell lymphomas. <i>Journal of Hematology and Oncology</i> , 2017, 10, 85.	6.9	233
31	Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2. <i>Journal of Experimental Medicine</i> , 2017, 214, 1371-1386.	4.2	144
32	Aggregation of Mod5 is affected by tRNA binding with implications for tRNA-mediated silencing. <i>FEBS Letters</i> , 2017, 591, 1601-1610.	1.3	5
33	Genetic and Functional Drivers of Diffuse Large B-Cell Lymphoma. <i>Cell</i> , 2017, 171, 481-494.e15.	13.5	804
34	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1826-1838.	2.0	135
35	The peptidyl-prolyl isomerase PIN1 relieves cyclin-dependent kinase 2 (CDK2) inhibition by the CDK inhibitor p27. <i>Journal of Biological Chemistry</i> , 2017, 292, 21431-21441.	1.6	16
36	Arsenic trioxide degrades NPM-ALK fusion protein and inhibits growth of ALK-positive anaplastic large cell lymphoma. <i>Leukemia</i> , 2017, 31, 522-526.	3.3	13

#	ARTICLE	IF	CITATIONS
37	Deficiency of Cks1 Leads to Learning and Long-Term Memory Defects and p27 Dependent Formation of Neuronal Cofilin Aggregates. <i>Cerebral Cortex</i> , 2017, 27, 11-23.	1.6	14
38	Chidamide in the treatment of peripheral T-cell lymphoma. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 347-352.	1.0	58
39	Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. <i>International Angiology</i> , 2017, 36, 1-20.	0.4	108
40	miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression. <i>Oncotarget</i> , 2017, 8, 11343-11355.	0.8	47
41	Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. <i>Oncotarget</i> , 2017, 8, 25455-25468.	0.8	10
42	Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789.	1.4	237
43	Diagnosis and management of extranodal NK/T cell lymphoma nasal type. <i>Expert Review of Hematology</i> , 2016, 9, 861-871.	1.0	71
44	Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 20520-20531.	0.8	40
45	Understanding the role of PIN1 in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 9921.	1.4	18
46	Receptor-type tyrosine-protein phosphatase \hat{p} directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma. <i>Blood</i> , 2015, 125, 1589-1600.	0.6	108
47	Nasal NK/T-cell lymphoma: RT, CT, or both. <i>Blood</i> , 2015, 126, 1400-1401.	0.6	36
48	Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. <i>Journal of Hematology and Oncology</i> , 2015, 8, 46.	6.9	23
49	T-cell lymphoma: Microenvironment-related biomarkers. <i>Seminars in Cancer Biology</i> , 2015, 34, 46-51.	4.3	27
50	<scp>LDH</scp> is an adverse prognostic factor independent of <scp>ISS</scp> in transplantâ€eligible myeloma patients receiving bortezomibâ€based induction regimens. <i>European Journal of Haematology</i> , 2015, 94, 330-335.	1.1	25
51	Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target. <i>Experimental and Molecular Medicine</i> , 2015, 47, e136-e136.	3.2	56
52	Invasive fungal infections after obinutuzumab monotherapy for refractory chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2015, 94, 165-167.	0.8	20
53	Whole Exome Sequencing of Type 1 and Type 2 Enteropathy-Associated T Cell Lymphoma Reveals Genetic Basis of Eatl Oncogenesis. <i>Blood</i> , 2015, 126, 575-575.	0.6	3
54	Abstract 3119: miR-296-5p and miR-874-3p control cell proliferation and apoptosis in HCC via regulation of PIN1 expression. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
55	Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. <i>Bone Marrow Transplantation</i> , 2014, 49, 902-906.	1.3	74
56	Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. <i>Leukemia</i> , 2014, 28, 865-870.	3.3	113
57	Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients. <i>Annals of Hematology</i> , 2014, 93, 493-498.	0.8	22
58	Increasing incidence of venous thromboembolism due to cancer-associated thrombosis in Hong Kong Chinese. <i>Thrombosis Research</i> , 2014, 134, 1157-1159.	0.8	5
59	Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2014, 12, 52.	1.8	35
60	Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab. <i>Journal of Clinical Virology</i> , 2014, 59, 255-258.	1.6	17
61	Management of Advanced NK/T-Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 233-242.	1.2	10
62	Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. <i>Lancet Oncology</i> , The, 2013, 14, e508-e523.	5.1	70
63	Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor. <i>American Journal of Hematology</i> , 2013, 88, 485-491.	2.0	15
64	How I treat NK/T-cell lymphomas. <i>Blood</i> , 2013, 121, 4997-5005.	0.6	260
65	PIN1 Inhibits Apoptosis in Hepatocellular Carcinoma through Modulation of the Antiapoptotic Function of Survivin. <i>American Journal of Pathology</i> , 2013, 182, 765-775.	1.9	51
66	Deficiency of the Cyclin-Dependent Kinase Inhibitor, <i>CDKN1B</i> , Results in Overgrowth and Neurodevelopmental Delay. <i>Human Mutation</i> , 2013, 34, 864-868.	1.1	12
67	Antifungal drug usage in haematologic patients during a 4-year period in an Asian university teaching hospital. <i>Internal Medicine Journal</i> , 2013, 43, 541-546.	0.5	4
68	Novel therapeutic agents for T-cell lymphomas. <i>Discovery Medicine</i> , 2013, 16, 27-35.	0.5	7
69	Indolent T-cell large granular lymphocyte leukaemia after haematopoietic SCT: a clinicopathologic and molecular analysis. <i>Bone Marrow Transplantation</i> , 2012, 47, 952-956.	1.3	30
70	Donor cell leukaemia after allogeneic haematopoietic SCT followed by prolonged thalidomide maintenance for multiple myeloma. <i>Bone Marrow Transplantation</i> , 2012, 47, 612-615.	1.3	0
71	Practical management of natural killer/T-cell lymphoma. <i>Current Opinion in Oncology</i> , 2012, 24, 480-486.	1.1	26
72	SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. <i>Blood</i> , 2012, 120, 2973-2980.	0.6	361

#	ARTICLE	IF	CITATIONS
73	Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. <i>Journal of Hematology and Oncology</i> , 2012, 5, 28.	6.9	13
74	The CDK Subunit CKS2 Counteracts CKS1 to Control Cyclin A/CDK2 Activity in Maintaining Replicative Fidelity and Neurodevelopment. <i>Developmental Cell</i> , 2012, 23, 356-370.	3.1	34
75	Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. <i>American Journal of Hematology</i> , 2012, 87, 663-668.	2.0	134
76	Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. <i>Clinical Transplantation</i> , 2012, 26, 679-683.	0.8	17
77	The Use of Clofarabine and Cytarabine Combination (CLARA) As Salvage Therapy for Relapsed and/or Refractory Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 1518-1518.	0.6	0
78	Synchronous Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly and Epstein-Barr virus-positive classical Hodgkin lymphoma. <i>Histopathology</i> , 2011, 59, 352-355.	1.6	4
79	Treatment algorithms for mature T-cell and natural killer-cell neoplasms. <i>Future Oncology</i> , 2011, 7, 1101-1112.	1.1	9
80	Primary immune thrombocytopenia responding to antithyroid treatment in a patient with Graves disease. <i>Annals of Hematology</i> , 2011, 90, 223-224.	0.8	18
81	T-cell prolymphocytic leukaemia: spontaneous immunophenotypical switch from CD4 to CD8 expression. <i>Annals of Hematology</i> , 2011, 90, 479-481.	0.8	9
82	Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. <i>Annals of Hematology</i> , 2011, 90, 1277-1281.	0.8	19
83	Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results. <i>Annals of Hematology</i> , 2011, 90, 1399-1407.	0.8	14
84	Effects of Azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT—a randomized double-blinded placebo-controlled study. <i>Bone Marrow Transplantation</i> , 2011, 46, 1551-1556.	1.3	55
85	T-cell large granular lymphocyte leukemia: an Asian perspective. <i>Annals of Hematology</i> , 2010, 89, 331-339.	0.8	34
86	Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type. <i>Advances in Hematology</i> , 2010, 2010, 1-5.	0.6	65
87	Absence of NPM1 promoter hypermethylation in human myelodysplastic syndrome. <i>Journal of Clinical Pathology</i> , 2010, 63, 1008-1011.	1.0	2
88	IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. <i>Journal of Neuroinflammation</i> , 2010, 7, 76.	3.1	150
89	Abstract 1212: PIN1 enhances the anti-apoptotic function of survivin in cancer cells. , 2010, , .		0
90	Protein-Losing Enteropathy Due to T-Cell Large Granular Lymphocyte Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 2097-2098.	0.8	5

#	ARTICLE	IF	CITATIONS
91	Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. <i>American Journal of Hematology</i> , 2009, 84, 302-305.	2.0	3
92	Non-nasal natural killer cell lymphoma: not non-nasal after all. <i>Annals of Hematology</i> , 2009, 88, 185-187.	0.8	29
93	Valganciclovir thrice weekly for prophylaxis against cytomegalovirus reactivation during alemtuzumab therapy. <i>Leukemia</i> , 2009, 23, 800-801.	3.3	11
94	High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. <i>Leukemia Research</i> , 2008, 32, 547-551.	0.4	22
95	Positron Emission Tomography/Computed Tomography in the Diagnosis of Multifocal Primary Hepatic Lymphoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5479-5480.	0.8	12
96	Treatment of Relapsed Acute Promyelocytic Leukemia with Oral Arsenic Trioxide: An Eleven-Year Experience. <i>Blood</i> , 2008, 112, 2958-2958.	0.6	0
97	Oral Arsenic Trioxide without Chemotherapy as Maintenance Therapy for Patients with Acute Promyelocytic Leukemia in First Complete Remission. <i>Blood</i> , 2008, 112, 2959-2959.	0.6	0
98	Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. <i>Blood</i> , 2007, 109, 740-746.	0.6	122
99	Pin1 Interacts With a Specific Serine-Proline Motif of Hepatitis B Virus X-Protein to Enhance Hepatocarcinogenesis. <i>Gastroenterology</i> , 2007, 132, 1088-1103.	0.6	121
100	Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab. <i>American Journal of Hematology</i> , 2007, 82, 108-111.	2.0	26
101	Fludarabine, mitoxantrone and dexamethasone as first-line treatment for T-cell large granular lymphocyte leukemia. <i>Leukemia</i> , 2007, 21, 2225-2226.	3.3	21
102	Molecular pathways in hepatocellular carcinoma. <i>Cancer Letters</i> , 2006, 240, 157-169.	3.2	86
103	PIN1 expression contributes to hepatic carcinogenesis. <i>Journal of Pathology</i> , 2006, 210, 19-25.	2.1	53
104	Subarachnoid haemorrhage: more than meets the eye. <i>British Journal of Haematology</i> , 2005, 132, 051220022257004.	1.2	1
105	Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. <i>Annals of Oncology</i> , 2005, 16, 206-214.	0.6	203
106	Detection of Intrahepatic Hepatitis B Virus DNA and Correlation with Hepatic Necroinflammation and Fibrosis. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3920-3924.	1.8	21
107	Null Mutation of the Lmo4 Gene or a Combined Null Mutation of the Lmo1 / Lmo3 Genes Causes Perinatal Lethality, and Lmo4 Controls Neural Tube Development in Mice. <i>Molecular and Cellular Biology</i> , 2004, 24, 2063-2073.	1.1	76
108	Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. <i>British Journal of Haematology</i> , 2004, 124, 754-761.	1.2	39

#	ARTICLE	IF	CITATIONS
109	Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 34, 57-61.	1.3	15
110	PIN1 overexpression and β -catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. <i>Oncogene</i> , 2004, 23, 4182-4186.	2.6	101
111	HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. <i>Hepatology</i> , 2004, 39, 1694-1701.	3.6	222
112	Natural Killer Cell Neoplasms. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 197-201.	2.1	6
113	Isolation of Antigen-Specific Intracellular Antibody Fragments as Single Chain Fv for Use in Mammalian Cells. , 2002, 185, 433-446.		4
114	Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. <i>Journal of Molecular Biology</i> , 2002, 317, 85-94.	2.0	87
115	A cutaneous sore with black eschar in a cowhide worker. <i>Lancet, The</i> , 2002, 360, 306.	6.3	2
116	Mouse Models of Human Chromosomal Translocations and Approaches to Cancer Therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 249-259.	0.6	17
117	Intracellular antibody-caspase-mediated cell killing: An approach for application in cancer therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 12266-12271.	3.3	59
118	Selection of antibodies for intracellular function using a two-hybrid in vivo system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 11723-11728.	3.3	174
119	Characterization of the Lmo4 gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping. <i>Mammalian Genome</i> , 1999, 10, 1089-1094.	1.0	13